What is HC Wainwright's Estimate for Harrow FY2026 Earnings?

Harrow, Inc. (NASDAQ:HROW - Free Report) - Analysts at HC Wainwright issued their FY2026 earnings estimates for shares of Harrow in a report issued on Monday, May 12th. HC Wainwright analyst Y. Chen expects that the company will post earnings per share of $0.40 for the year. HC Wainwright has a "Buy" rating and a $60.00 price objective on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share.

Separately, B. Riley decreased their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st.

Harrow Stock Performance

NASDAQ HROW traded down $0.72 during midday trading on Wednesday, hitting $27.69. The company had a trading volume of 100,436 shares, compared to its average volume of 496,526. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The stock has a market cap of $1.02 billion, a price-to-earnings ratio of -29.51 and a beta of 0.41. The firm has a fifty day simple moving average of $25.02 and a two-hundred day simple moving average of $31.81. Harrow has a fifty-two week low of $15.97 and a fifty-two week high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%.

Institutional Trading of Harrow

Institutional investors have recently made changes to their positions in the business. Barclays PLC lifted its holdings in Harrow by 301.9% during the 3rd quarter. Barclays PLC now owns 52,593 shares of the company's stock valued at $2,365,000 after purchasing an additional 39,506 shares during the last quarter. Brookstone Capital Management acquired a new position in shares of Harrow in the 4th quarter valued at $275,000. SG Americas Securities LLC grew its holdings in shares of Harrow by 158.5% in the 4th quarter. SG Americas Securities LLC now owns 30,689 shares of the company's stock valued at $1,030,000 after buying an additional 18,815 shares during the period. Sonora Investment Management Group LLC acquired a new position in shares of Harrow in the fourth quarter valued at approximately $518,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Harrow by 10.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock valued at $253,000 after buying an additional 727 shares during the period. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.